CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

ABSTRACT:

Objective

Cognitive decline associated with Parkinson disease (PD) is common and highly disabling. Biomarkers that help identify patients at risk for cognitive decline would be useful additions to the clinical management of the disease.

Methods

A total of 45 patients with PD were enrolled in this prospective cohort study and had at least 1 yearly longitudinal follow-up evaluation. CSF was collected at baseline and cognition was assessed at baseline and follow-up visits using the Mattis Dementia Rating Scale (DRS-2). CSF was tested for amyloid β 1-42 (Aβ(1-42)), p-tau(181p), and total tau levels using the Luminex xMAP platform. Mixed linear models were used to test for associations between baseline CSF biomarker levels and change in cognition over time.

Results

Lower b

SUBMITTER: Siderowf A 

PROVIDER: S-EPMC2942062 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature